Admin

Novo Nordisk "wins by volume": High-dose semaglutide trial shows 19% weight loss effect, but still lags behind Lilly’s competing product.

Novo Nordisk "wins by volume": High-dose semaglutide trial shows 19% weight loss effect, but still lags behind Lilly’s competing product.

``` Recently, Novo Nordisk announced results of a clinical trial, showing that its much-anticipated Semaglutide demonstrated more significant weight loss effects when the dosage was tripled. Semaglutide is Novo Nordisk’s flagship product, marketed under the brands Wegovy for weight loss and Ozempic for diabetes. In two recent phase 3 clinical
Admin
Goldman Sachs sharply raises Oracle's target price but maintains "Neutral" rating: Massive capital expenditures put significant pressure on short-term profits.

Goldman Sachs sharply raises Oracle's target price but maintains "Neutral" rating: Massive capital expenditures put significant pressure on short-term profits.

``` After Oracle released explosive guidance, its stock price once soared by 36%. Goldman Sachs significantly raised Oracle’s target price in its latest report but maintained a “Neutral” rating, believing that the massive capital expenditures will push back the cash flow breakeven point to fiscal year 2029, and that it
Admin